Micro RNA and its application in the preparation of antitumor drugs

Abstract

Provided are an miR-34a-5p mutant and the use of same in preparing anti-tumor drugs. The mutant is the miR-34a-5p sequence with any base at positions 10-22 of the 5' end thereof being mutated to n, wherein n is A, C, G or U. The mutant and the complementary chain thereof can inhibit the expression level of PD-L1, B7-H3 and B7-H4 proteins in tumor cells and inhibit growth and / or proliferation of tumor cells, and meanwhile have no significant impact on the secretion of cytokines in serum.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to microRNA and its application in the preparation of antitumor drugs. Background technique [0002] The morbidity and mortality of malignant tumors in our country are increasing year by year, which has attracted more and more attention from the medical field, and has also become a major topic of basic research and clinical research. Although some progress has been made in tumor treatment, there is still a certain distance from the fundamental improvement of survival period and the requirements for quality of life. More efforts are still needed to explore safer and more effective adjuvant therapy. At present, tumor immunotherapy has become an effective therapy after surgery, chemotherapy and radiotherapy, and is widely used in clinic, especially the blocking therapy based on immune card control points. Effective anti-tumor immunotherapy depends on the efficient activatio...

AI Technical Summary

Problems solved by technology

Although preliminary clinical trial results showed that MRX34 had acceptable efficacy and safety, the clinical trial was discontinued due to cytokine storm in 5 patients

Images